Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology-Reference-Cited by-同舟云学术

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Published:2022-08 Issue:8 Volume:20 Page:925-951
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Haddad Robert I¹,Bischoff Lindsay²,Ball Douglas³,Bernet Victor⁴,Blomain Erik⁵,Busaidy Naifa Lamki⁶,Campbell Michael⁷,Dickson Paxton⁸,Duh Quan-Yang⁹,Ehya Hormoz¹⁰,Goldner Whitney S.¹¹,Guo Theresa¹²,Haymart Megan¹³,Holt Shelby¹⁴,Hunt Jason P.¹⁵,Iagaru Andrei⁵,Kandeel Fouad¹⁶,Lamonica Dominick M.¹⁷,Mandel Susan¹⁸,Markovina Stephanie¹⁹,McIver Bryan²⁰,Raeburn Christopher D.²¹,Rezaee Rod²²,Ridge John A.¹⁰,Roth Mara Y.²³,Scheri Randall P.²⁴,Shah Jatin P.²⁵,Sipos Jennifer A.²⁶,Sippel Rebecca²⁷,Sturgeon Cord²⁸,Wang Thomas N.²⁹,Wirth Lori J.³⁰,Wong Richard J.²⁵,Yeh Michael³¹,Cassara Carly J.³²,Darlow Susan³²

Affiliation:

1. 1Dana-Farber/Brigham and Women’s Cancer Center;

2. 2Vanderbilt-Ingram Cancer Center;

3. 3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

4. 4Mayo Clinic Cancer Center;

5. 5Stanford Cancer Institute;

6. 6The University of Texas MD Anderson Cancer Center;

7. 7UC Davis Comprehensive Cancer Center;

8. 8St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;

9. 9UCSF Helen Diller Family Comprehensive Cancer Center;

10. 10Fox Chase Cancer Center;

11. 11Fred & Pamela Buffett Cancer Center;

12. 12UC San Diego Moores Cancer Center;

13. 13University of Michigan Rogel Cancer Center;

14. 14UT Southwestern Simmons Comprehensive Cancer Center;

15. 15Huntsman Cancer Institute at the University of Utah;

16. 16City of Hope National Medical Center;

17. 17Roswell Park Comprehensive Cancer Center;

18. 18Abramson Cancer Center at the University of Pennsylvania;

19. 19Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

20. 20Moffitt Cancer Center;

21. 21University of Colorado Cancer Center;

22. 22Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

23. 23Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

24. 24Duke Cancer Institute;

25. 25Memorial Sloan Kettering Cancer Center;

26. 26The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

27. 27University of Wisconsin Carbone Cancer Center;

28. 28Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

29. 29O’Neal Comprehensive Cancer Center at UAB;

30. 30Massachusetts General Hospital Cancer Center;

31. 31UCLA Jonsson Comprehensive Cancer Center; and

32. 32National Comprehensive Cancer Network.

Abstract

Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma).

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/20/8/article-p925.xml

Reference420 articles.

1. The goitrous patient with an elevated serum calcitonin--what to do?;Horvit;J Clin Endocrinol Metab,1997

2. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009

3. Update to the College of American Pathologists reporting on thyroid carcinomas;Ghossein;Head Neck Pathol,2009

4. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma;Vitale;J Clin Endocrinol Metab,2000

5. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors;Kouvaraki;Thyroid,2005

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy;Annals of Diagnostic Pathology;2024-04

2. Establishment and verification of the first prognostic nomograms in locally advanced thyroid cancer based on the analysis of clinical and follow-up information on 2396 patients;Heliyon;2024-02

3. Les tests moléculaires et autres techniques ancillaires en cytologie thyroïdienne selon Bethesda 2023;Annales de Pathologie;2024-02

4. The m6A methyltransferase METTL3 drives thyroid cancer progression and lymph node metastasis by targeting LINC00894;Cancer Cell International;2024-01-30

5. The Impact of Total Tumor Diameter on Lymph Node Metastasis and Tumor Recurrence in Papillary Thyroid Carcinomas;Diagnostics;2024-01-26